BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Vir Bio’s COVID-19 Antibody Therapy Could be Great, But Will It Be Too Late?

  San Francisco-based Vir Biotechnology and its chief executive officer, George Scangos, believe it has a terrific antibody therapy against SARS-CoV-2, the virus that causes COVID-19. But is it too late to the game?

  November 11, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  BioSpace Global Roundup, Nov. 12

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  November 11, 2020

   · 

  9 min read

   · 

  Alex Keown
• 

  Drug Development

  Moderna’s Personalized Cancer Vaccine Shows Promise in Early-Stage Trial

  Moderna released interim data from the expansion cohort of its ongoing Phase I trial of its mRNA personalized cancer vaccine, mRNA-4157.

  November 11, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  Pfizer’s Positive Vaccine Data is a Relief for Many, but Logistical Hurdles Remain

  Even if the vaccine is given the greenlight by regulatory agencies, it will still take some time for the vaccine to be distributed to a wide swath of the population.

  November 11, 2020

   · 

  5 min read

   · 

  Alex Keown
• 

  Job Trends

  Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis

  Jeff Dage, Ph.D., senior research adviser at Eli Lilly and Company, presented the case for P-tau in blood as an accurate biomarker.

  November 11, 2020

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Pfizer’s Positive Trial Results Hint at More Possibilities for Abrocitinib

  Pfizer announced today that it has received positive top-line results from the Phase III JADE REGIMEN study, examining abrocitinib for the treatment of severe atopic dermatitis.

  November 11, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  Business

  Mispro’s Emerging Business Model Helps Biopharma Companies Get to Market Faster

  This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing.

  November 11, 2020

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Business

  IniPharm Closes on $35 Million Series A to Fund NASH Drug Development

  5AM Ventures and Wu Capital joined existing investors Frazier Healthcare Partners and Jubilant Biosys Limited.

  November 11, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Russia Claims its Sputnik V Vaccine is 92% Effective Following Interim Analysis

  Days after Pfizer and BioNTech announced their mRNA vaccine for COVID-19 demonstrated 90% efficacy at an interim analysis, Russia is claiming the vaccine it authorized in the fight against the novel coronavirus is 92% effective following an interim analysis of its ongoing Phase III study.

  November 11, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  New CDC Guidance Calls for Universal Mask Mandates to Protect Wearers, Others from COVID-19

  After months of urging the public to wear masks and facial coverings to help stop infected people from spreading COVID-19, the Centers for Disease Control and Prevention now states in newly released guidance that masks also protected the mask wearer from being infected.

  November 11, 2020

   · 

  3 min read

   · 

  Brandon May